Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
ACCESSWIRE
Advancing Dyadic s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial
Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeutics
Goal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccines
Engaged CR2O to manage and support further preclinical and clinical development
Initiated toxicology study
cGMP manufacturing run in progress
Collaborating on next-generation COVID-19 variant vaccines and/or boosters through Korea and Southeast Asia vaccine development partnership with Medytox (